Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BK6R
|
|||
| Drug Name |
PMID25656651-Compound-36c
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H14F3N3O2
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)N3C=CN=C3
|
|||
| InChI |
1S/C18H14F3N3O2/c1-12-2-3-13(10-16(12)24-9-8-22-11-24)17(25)23-14-4-6-15(7-5-14)26-18(19,20)21/h2-11H,1H3,(H,23,25)
|
|||
| InChIKey |
VTOBGTLKLODAIL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.